Physician profile
Joseph L Becker
NPI 1336770759
$1,974.13
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $558 · 2022: $827 · 2023: $189 · 2024: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $534 · Education: $54.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $534.06 |
| Education | $54.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $550.42 | 2021-2024 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $458.47 | 2021-2024 | |
| Opko Pharmaceuticals, LLC | $244.64 | 2021-2023 | Rayaldee |
| Akebia Therapeutics INC | $221.74 | 2021-2022 | |
| Amgen INC. | $111.30 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.65 | 2023-2024 | Jardiance |
| Calliditas Therapeutics US INC. | $78.81 | 2022-2024 | |
| Glaxosmithkline, LLC. | $48.10 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $36.65 | 2022-2023 | Jynarque |
| Vifor Pharma, INC. | $30.65 | 2021-2023 | Korsuva, Veltassa |
| Csl Behring | $25.15 | 2021 | |
| Fresenius USA Marketing, INC. | $19.68 | 2022 | |
| Aurinia Pharma U.S., INC. | $17.62 | 2022 | |
| Travere Therapeutics, INC. | $17.26 | 2024 | |
| Novartis Pharmaceuticals Corporation | $15.99 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Becker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.